Advertisement

Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Multiple myeloma, high-dose treatment and autologous stem cell transplantation—current status

Abstract

High-dose chemo-radiotherapy with autologous stem cell transplantation (ASCT) has introduced the concept of complete remission for multiple myeloma, and can improve survival and life quality for selected groups of myeloma patients. A number of prognostic factors have been identified, where ASCT in early disease, i.e. as part of front-line treatment, seems to be of particular importance for a favourable outcome. Even so, most myeloma patients will not be cured by high-dose therapy, but new strategies such as repeated autografting and post-graft alpha-inter-feron maintenance treatment seem to add additional advantages with respect to survival and freedom of disease progression. The technical development has enabled efficientin vitro myeloma cell depletion of the autograft as well as highly sensitive detection of minimal residual disease after treatment, but the clinical significance of these issues remains to be determined, and this question is addressed in ongoing gene marking studies. The application of novel therapeutic principles, e.g. gene therapy and immunotherapy, might further ameliorate the outcome for patients with multiple myeloma.

This is a preview of subscription content, log in to check access.

References

  1. 1

    Barlogie, B. and Gahrton, G. (1991) Bone marrow transplantation in multiple myeloma.Bone Marrow Transplant. 7, 71–9.

  2. 2

    McElwain, T.J. and Powles, R.L. (1983) High dose intravenous melphalan for plasma cell leukaemia and myeloma.Lancet ii, 822–4.

  3. 3

    Selby, P.J., McElwain, T.J., Nandi, A.C.et al. (1987) Multiple myeloma treated with high dose intravenous melphalan.Br. J. Haematol. 66, 55–62.

  4. 4

    Lokhorst, H.M., Meuwissen, O.J.A.T., Verdonck, L.F. and Dekker, A.W. (1992) High-risk multiple myeloma treated with high-dose melphalan.J. Clin. Oncol. 10, 47–51.

  5. 5

    Cunningham, D., Paz-Ares, L., Gore, M.E.et al. (1994) High- dose melphalan for multiple myeloma: long-term follow-up data.J. Clin. Oncol. 12, 764–8.

  6. 6

    Barlogie, B., Hall, R., Zander, A., Dicke, K. and Alexanian, R. (1986) High-dose melphalan with autologous bone marrow transplantation for multiple myeloma.Blood 67, 1298–301.

  7. 7

    Barlogie, B., Alexanian, R., Dicke, K.A.et al. (1987) Highdose chemoradiotherapy and autologous bone marrow transplantation for resistant multiple myeloma.Blood 70, 869–72.

  8. 8

    Gore, M.E., Viner, C, Meldrum, M.et al. (1989) Intensive treatment of multiple myeloma and criteria for complete remission.Lancet 2, 879–82.

  9. 9

    Attal, M., Harousseau, J.-L., Stoppa, A.-M.et al. (1995) High dose therapy in multiple myeloma: final analysis of a prospective randomized study of the ‘Intergroupe Français du Myelome’ (IFM 90).Blood 86, suppl. 1, 124a.

  10. 10

    Barlogie, B., Alexanian, R., Smallwood, L.et al. (1988) Prognostic factors with high-dose melphalan for refractory multiple myeloma.Blood 72, 2015–9.

  11. 11

    Jagannath, S., Barlogie, B., Dicke, K.et al. (1990) Autologous bone marrow transplantation in multiple myeloma: Identification of prognostic factors.Blood 76, 1860–6.

  12. 12

    Björkstrand, B., Goldstone, A.H., Ljungman, P.et al. (1994) Prognostic factors in autologous stem cell transplantation for multiple myeloma: An EBMT registry study.Leuk. Lymphoma 15, 265–72.

  13. 13

    Björkstrand, B., Ljungman, P., Alegre, A.et al. (1996) Autologous stem cell transplantation (ASCT) in myeloma - an EBMT registry update.Bone Marrow Transplant. 17, suppl. 1, S14.

  14. 14

    Attal, M., Huguet, F., Schlaifer, D.et al. (1992) Intensive combined therapy for previously untreated aggressive myeloma.Blood 79, 1130–6.

  15. 15

    Harousseau, J.-L., Attal, M., Divine, M.et al. (1995) Autologous stem cell transplantation after first remission induction treatment in multiple myeloma: ta report of the French registry on autologous transplantation in multiple myeloma.Blood 85, 3077–85.

  16. 16

    Björkstrand, B., Ljungman, P., Bird, J.M.et al. (1995) Autologous stem cell transplantation in multiple myeloma: results of the European Group for Bone Marrow Transplantation.Stem Cells 13, suppl. 2, 140–6.

  17. 17

    Vesole, D.H., Barlogie, B., Jagannath, S.et al. (1994) Highdose therapy for refractory multiple myeloma: Improved prognosis with better supportive care and double transplants.Blood 84, 950–6.

  18. 18

    Dimopoulos, M.A., Hester, J., Huh, Y., Champlin, R. and Alexanian, R. (1994) Intensive chemotherapy with blood progenitor transplantation for primary resistant multiple myeloma.Br. J. Haematol. 87, 730–4.

  19. 19

    Tricot, G., Jagannath, S., Vesole, D.H., Crowley, J. and Barlogie, B. (1995) Relapse of multiple myeloma after autologous transplantation:survival after salvage therapy.Bone Marrow Transplant. 16, 7–11.

  20. 20

    Singhai, S., Powles, R., Cunningham, D.et al. (1995) Repeat autografts for relapsed myeloma.Blood 86, suppl. 1, 207a.

  21. 21

    Harousseau, J.L., Milpied, N., Garand, R. and Bourhis, J.H. (1987) High dose melphalan and autologous bone marrow transplantation in high risk myeloma.Br. J. Haematol. 67, 493.

  22. 22

    Harousseau, J.L., Milpied, N., Laporte, J.P.et al (1992) Double-intensive therapy in high-risk myeloma.Blood 79, 2827–33.

  23. 23

    Jagannath, S., Vesole, D., Glenn, L. and Barlogie, B. (1992) Total therapy (TT) with intensive remission induction (IRI) and double autotransplants (Tx) for multiple myeloma (MM).Blood 80, suppl. 1, 362a.

  24. 24

    Jagannath, S., Vesole, D., Tricot, G. and Barlogie, B. (1994) Total therapy (TT) for newly diagnosed multiple myeloma.Br. J. Haematol. 87, suppl. 1, 221.

  25. 25

    Barlogie, B., Jagannath, S., Vesole, D. and Tricot, G. (1994) Hematopoietic stem cell autografts in support of myeloa-blative therapy for multiple myeloma.J. Hematother. 3, 149–53.

  26. 26

    Barlogie, B., Crowley, J., Jagannath, S.et al. (1995) Superior outcome after early autotransplantation (AT) with ‘total therapy’ (TT) compared to standard SWOG treatment (ST) for multiple myeloma (MM).Blood 86, suppl. 1, 207a.

  27. 27

    Björkstrand, B., Ljungman, P., Bird, J.M., Samson, D. and Gahrton, G. (1995) Double high-dose chemo-radiotherapy with autologous stem cell transplantation can induce molecular remissions in multiple myeloma.Bone Marrow Transplant. 15, 367–71.

  28. 28

    Björkstrand, B., Ljungman, P., Bird, J.M., Samson, D. and Gahrton, G. (1995) Double high-dose intensification with autologous hematopoietic stem cell transplantation can induce long-term molecular remissions in multiple myeloma.Vth International Workshop on Multiple Myeloma. La Baule.

  29. 29

    Björkstrand, B. (1995) 474 autotransplants in multiple mye- loma - results of the EBMT.Vth International Workshop on Multiple Myeloma. La Baule, 3.32.

  30. 30

    Ventura, G.J., Barlogie, B., Hester, J.P.et al. (1990) High dose cyclophosphamide, BCNU and VP-16 with autologous blood stem cell support for refractory multiple myeloma.Bone Marrow Transplant. 5, 265–8.

  31. 31

    Schüler, G., Nimer, S., Vescio, R.et al. (1994) Phase I-II study of busulfan and cyclophosphamide conditioning for transplantation in advanced multiple myeloma.Bone Marrow Transplant. 14, 131–6.

  32. 32

    Alegre, A., Lamana, M., Arranz, R.et al. (1995) Busulfan and melphalan as conditioning regimen for autologous peripheral blood stem cell transplantation in multiple myeloma.Br. J. Haematol. 91, 380–6.

  33. 33

    Harousseau, J.-L., Attal, M., Divine, M.et al. (1995) Comparison of autologous bone marrow transplantation and peripheral blood stem cell transplantation after first remission induction treatment in multiple myeloma.Bone Marrow Transplant. 15, 963–9.

  34. 34

    Vescio, R.A., Han, E.J., Lee, J.C.et al. (1995) Quantitative comparison of multiple myeloma tumor contamination in bone marrow harvest and leukapheresis autografts.Blood 86, suppl. 1, 234a.

  35. 35

    Bird, J.M., Bloxham, D., Samson, D.et al. (1994) Molecular detection of clonally rearranged cells in peripheral blood progenitor cell harvests from multiple myeloma patients.Br. J. Haematol. 88, 110–6.

  36. 36

    Mariette, X., Fermand, J.-P. and Brouet, J.-C. (1994) Myeloma cell contamination of peripheral blood stem cell grafts in patients with multiple myeloma treated by high-dose therapy.Bone Marrow Transplant. 14, 47–50.

  37. 37

    Corradini, P., Voena, C, Astoln, M.et al. (1995) High-dose sequential chemoradiotherapy in multiple myeloma: residual tumor cells are detectable in bone marrow and peripheral blood cell harvests and after autografting.Blood 85, 1596–602.

  38. 38

    Siena, S., Bregni, M., Brando, B., Ravagnani, F., Bonadon-na, G. and Gianni, A.M. (1989) Circulation of CD34+ hematopoietic stem cells in the peripheral blood of high-dose cyclophosphamide-treated patients: Enhancement by intravenous recombinant human granulocyte-macrophage colony-stimulating factor.Blood 74, 1905–14.

  39. 39

    Myint, H., Orchard, J.A., Figes, A.E. and Tiller, M. (1995) Comparison of cyclophosphamide 1.5 gm/m2 with G-CSF vs. 3-4 g/m2 with G-CSF for the mobilisation of PBPC in heavily pretreated patients with haematological malignancies.Blood 86, suppl. 1, 409a.

  40. 40

    Goldschmidt, H., Hegenbart, U., Wallmeier, M., Haas, R. and Hunstein, W. (1996) Peripheral blood progenitor cell mobilization in prerreated patients with multiple myeloma - a significantly lower B-cell content in leukapheresis products following 7 g/m2 compared to 4 g/m2 cyclophosphamide.Bone Marrow Transplant. 17, suppl. 1, S14.

  41. 41

    Gazitt, Y., Tian, E., Barlogie, B.et al. (1996) Differential mobilization of myeloma cells and normal hematopoietic stem cells in multiple myeloma after treatment with cyclophosphamide and granulocyte-macrophage colony-stimulating factor.Blood 87, 805–11.

  42. 42

    Lemoli, R.M., Fortuna, A., Motta, M.R.et al. (1996) Concomitant mobilization of plasma cells and hematopoietic progenitors into peripheral blood of multiple myeloma patients: positive selection and transplantation of enriched CD34+ cells to remove circulating tumor cells.Blood 87, 1625–34.

  43. 43

    Mauch, P., Ferrara, J. and Hellman, S. (1989) Stem cell self-renewal considerations in bone marrow transplantation.Bone Marrow Transplant. 4, 601–7.

  44. 44

    Neben, S., Hemman, S., Montgomery, M., Ferrara, J. and Mauch, P. (1993) Hematopoietic stem cell deficit of transplanted bone marrow previously exposed to cytotoxic agents.Exp. Hematol 21, 156–62.

  45. 45

    Tricot, G., Jagannath, S., Vesole, D.et al. (1995) Peripheral blood stem cell transplants for multiple myeloma: identification of favorable variables for rapid engraftment in 225 patients.Blood 85, 588–96.

  46. 46

    Billadeau, D., Quam, L., Thomas, W.et al. (1992) Detection and quantification of malignant cells in the peripheral blood of multiple myeloma patients.Blood 80, 1818–24.

  47. 47

    Dreyfus, F., Meile, J., Quarre, M.-C. and Pillier, C. (1993) Contamination of peripheral blood by monoclonal B cells following treatment of multiple myeloma by high-dose chemotherapy.Br. J. Haematol 85, 411–2.

  48. 48

    Owen, R.G., Johnson, R.J., Smith, G.M., Child, J.A., Galvin, M.C. and Morgan, GJ. (1995) PCR assessment of the efficacy of CD34 selection (CellPro) in multiple myeloma (MM) and follicular lymphoma (FL).Bone Marrow Transplant. 15, suppl. 2, S107.

  49. 49

    Lemoli, R.M., Visani, G., Gobbi, M.et al. (1989) Normal myeloid progenitors (CFU-GM) in multiple myeloma: a preliminary study in view of autologous BMT.Bone Marrow Transplant. 4, 373–7.

  50. 50

    Reece, D.E., Barnett, M.J., Connors, J.M.et al. (1993) Treatment of multiple myeloma with intensive chemotherapy followed by autologous BMT using marrow purged with 4-hydroperoxycyclophosphamide.Bone Marrow Transplant. 11, 139–46.

  51. 51

    Anderson, K.C., Barut, B.A., Ritz, J.et al. (1991) Monoclonal antibody-purged autologous bone marrow transplantation therapy for multiple myeloma.Blood 77, 712–20.

  52. 52

    Rhodes, E.G.H., Baker, P.K., Rhodes, J.M., Davies, J.M. and Duguid, J.K.M. (1994) Autologous bone marrow transplantation for myeloma patients using PNA- and CD19-purged marrow rescue.Bone Marrow Transplant. 13, 795–9.

  53. 53

    Berneman, Z.N., Chen, Z.-Z., Ramael, M., van Hoof, V. and Peetermans, M.E. (1989) Human long-term bone marrow cultures, (HLTBMCs) in myelomatous disorders.Leukemia 3, 151–4.

  54. 54

    Visani, G., Lemoli, R.M., Dinota, A.et al. (1989) Evidence that long-term bone marrow culture of patients with multiple myeloma favors normal hemopoietic proliferation.Transplantation 48, 1026–31.

  55. 55

    Stewart, A.K., Prince, H.M., Sutherland, D.R., Cappe, D., Nanji, S. and Dubé, I.D. (1995) Retroviral mediated gene transfer in multiple myeloma (MM).Blood 86, suppl. 1, 245a.

  56. 56

    Vescio, R.A., Hong, C.H., Cao, J.et al (1994) The hemato-poietic stem cell antigen, CD34, is not expressed on the malignant cells in multiple myeloma.Blood 84, 3283–90.

  57. 57

    Gazitt, Y., Reading, C.C., Hoffman, R.et al. (1995) Purified CD34+ Lin- Thy+ stem cells do not contain clonal myeloma cells.Blood 86, 381–9.

  58. 58

    Takishita, M., Kosaka, ML, Goto, T. and Saito, S. (1994) Cellular origin and extent of clonal involvement in multiple myeloma: genetic and phenotypic studies.Br. J. Haematol. 87, 735–42.

  59. 59

    Belch, A.R., Szczepek, A., Bergsagel, P.L. and Pilarski, L.M. (1995) Circulating CD34+ cells from peripheral blood in multiple myeloma include B cells with patient-specific IgH CDR3 sequences and CD34 mRNA as well as DNA hyperdiploidy and N-ras mutation.Blood 86, suppl. 1, 276a.

  60. 60

    Vescio, R., Cao, J., Hong, C.et al. (1994) CD34-positive Ceprate selection leads to a 4-5 log reduction in rumor burden in myeloma PBC autografts based on PCR and Poisson distribution analysis.Blood 84, suppl. 1, 399a.

  61. 61

    Bourhis, J.H., Beaujean, F., Bayle, C.et al. (1994) Auto-logous transplantation of CD34 + selected peripheral hematopoietic progenitors (PHP) leads to durable engraftment in multiple myeloma (MM) patients (pts) following a myeloablative intensive therapy.Blood 84, suppl. 1, 209a.

  62. 62

    Schiller, G., Vescio, R., Freytes, C.et al. (1995) Transplantation of CD34+ peripheral blood progenitor cells after high-dose chemotherapy for patients with advanced multiple myeloma.Blood 86, 390–7.

  63. 63

    Deane, M. and Norton, J.D. (1991) Detection of immuno-globulin gene rearrangement in B-cell neoplasias by poly-merase chain reaction gene amplification.Leuk. Lymphoma 5, 9–22.

  64. 64

    Bird, J.M., Russell, N.H. and Samson, D. (1993) Minimal residual disease after bone marrow transplantation for multiple myeloma: evidence for cure in long-term survivors.Bone Marrow Transplant. 12, 651–4.

  65. 65

    Brenning, G. (1985) Thein vitro effect of leucocyte alpha-interferon on human myeloma cells in a semisolid agar culture system.Scand. J. Haematol 35, 178–85.

  66. 66

    Brenning, G., Åhre, A. and Nilsson, K. (1985) Correlation betweenin vitro andin vivo sensitivity to human leucocyte interferon in patients with multiple myeloma.Scand. J. Haematol. 35, 543–9.

  67. 67

    Åhre, A., Björkholm, M., Mellstedt, H.et al. (1984) Human leukocyte interferon and intermittent high-dose melpha-lan-prednisone administration in the treatment of multiple myeloma: A randomized clinical trial from the Myeloma Group of Central Sweden.Cancer Treatm. Rep. 68, 1331–8.

  68. 68

    Österborg, A., Björkholm, M., Björeman, M.et al. (1993) Natural interferon-± in combination with melphalan/pre-dnisone versus melphalan/prednisone in the treatment of multiple myeloma stages II and III: A randomized study from the Myeloma Group of Central Sweden.Blood 81, 1428–34.

  69. 69

    Westin, J., Rödjer, S., Turesson, I., Cortelezzi, A., Hjorth, M. and Zador, G. (1995) Interferon alfa-2b versus no maintenance therapy during the plateau phase in multiple myeloma: a randomized study.Br. J. Haematol 89, 561–8.

  70. 70

    Powles, R., Cunningham, D., Malpas, J.S.et al. (1994) A randomised trial of maintenance therapy with Intron-A following high-dose melphalan and ABMT in myeloma.Blood 84, suppl. 1, 535a.

  71. 71

    Fermand, J.P., Ravaud, P., Chevret, S.et al. (1995) High dose therapy (HDT) and autologous blood stem cell transplantation (ABSCT) versus conventional chemotherapy with HDT rescue in multiple myeloma (MM): Results of a prospective randomized trial.Blood 86, suppl. 1, 205a.

  72. 72

    Henon, P., Donatini, B., Eisenmann, J.C., Becker, M. and Beck-Wirth, G. (1995) Comparative survival, quality of life and cost-effectiveness of intensive therapy with autologous blood stem cell transplantation or conventional chemotherapy in multiple myeloma.Bone Marrow Transplant. 16, 19–25.

  73. 73

    Harousseau, J.L., Attal, M., Reiffers, J.et al. (1992) Autologous hemopoietic stem cell transplantation in multiple myeloma. A report of the French Registry.Blood 80, suppl 1, 361a.

  74. 74

    Cunningham, D., Paz-Ares, L., Milan, S.et al (1994) Highdose melphalan and autologous bone marrow transplantation as consolidation in previously untreated myeloma.J. Clin. Oncol 12, 759–63.

  75. 75

    Alexanian, R., Dimopoulos, M., Smith, T., Delasalle, K., Barlogie, B. and Champlin, R. (1994) Limited value of myeloablative therapy for late multiple myeloma.Blood 83, 512–6.

  76. 76

    Björkstrand, B., Gahrton, G., Dilber, M. S., Ljungman, P., Smith, C.I.E. and Xanthopoulos, K.G. (1994) Retroviral-mediated gene transfer of CD34-enriched bone marrow-and peripheral blood cells during autologous stem cell transplantation for multiple myeloma.Human Gene Ther. 5, 1281–8.

  77. 77

    Stewart, A.K., Dubé, I.D., Kamel-Reid, S. and Keating, A. (1995) A phase I study of autologous bone marrow transplantation with stem cell gene marking in multiple myeloma.Human Gene Ther. 6, 107–19.

  78. 78

    Dunbar, C.E., Cottier-Fox, M., O’Shaughnessy, J.A.et al (1995) Retrovirally marked CD34-enriched peripheral blood and bone marrow cells contribute to long-term engraftment after autologous transplantation.Blood 85, 3048–57.

  79. 79

    Gribben, J.G., Neuberg, D., Freedman, A.S.et al (1993) Detection by polymerase chain reaction of residual cells with the bcl-2 translocation is associated with increased risk of relapse after autologous bone marrow transplantation for B-cell lymphoma.Blood 81, 3449–57.

  80. 80

    Kolb, HJ., Mittermuller, J., Clemm, C.et al. (1990) Donor leukocyte transfusions for treatment of recurrent chronic myelogenous leukemia in marrow transplant patients.Blood 76, 2462–5.

  81. 81

    Tricot, G., Vesole, D.H., Jagannath, S., Hilton, J., Munshi, N. and Barlogie, B. (1996) Graft-versus-myeloma effect: proof of principle.Blood 87, 1196–8.

  82. 82

    Dilber, M.S., Abedi, M.R., Björkstrand, B. et al. (1996) Suicide gene therapy for plasma cell tumors.Blood (in press).

  83. 83

    Klein, B., Wijdenes, J., Zhang, X.G.et al. (1991) Murine anti-interleuchin-6 monoclonal antibody therapy for a patient with plasma cell leukemia.Blood 78, 1198–204.

  84. 84

    Attisano, C, Bianchi, A., Montacchini, L.et al. (1994) Generation of anti-tumour activity by OKT3-stimulation in multiple myeloma:in vitro inhibition of autologous haemopoiesis.Br. J. Haematol 87, 494–502.

  85. 85

    Kwak, L.W., Taub, D.D., Duffey, P.L.et al. (1995) Transfer of myeloma idiotype-specific immunity from an actively immunized marrow donor.Lancet 345, 1016–20.

  86. 86

    Yi, Q., Österborg, A., Bergenbrant, S., Mellstedt, H., Holm, G. and Lefvert, A.-K. (1995) Idiotype-reactive T cell subsets and tumor load in monoclonal gammopathies.Blood 86, 3043–50.

  87. 87

    Yi, Q. and Österborg, A. (1996) Idiotype-specific T cells in multiple myeloma: targets for an immunotherapeutic intervention?Med. Oncol. (in press).

  88. 88

    Fermand, J.-P., Chevret, S., Ravaud, P.et al. (1993) Highdose chemoradiotherapy and autologous blood stem cell transplantation in multiple myeloma: Results of a phase II trial involving 63 patients.Blood 82, 2005–9.

  89. 89

    Dimopoulos, M.A., Alexanian, R., Przepiorka, D.et al. (1993) Thiotepa, busulfan, and cyclophosphamide: A new preparative regimen for autologous marrow or blood stem cell transplantation in high-risk multiple myeloma.Blood 82, 2324–8.

  90. 90

    Anderson, K.C., Andersen, J., Soiffer, R.et al. (1993) Monoclonal antibody-purged bone marrow transplantation therapy for multiple myeloma.Blood 82, 2568–76.

Download references

Author information

Correspondence to Bo Björkstrand.

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Björkstrand, B. Multiple myeloma, high-dose treatment and autologous stem cell transplantation—current status. Med Oncol 13, 23–30 (1996). https://doi.org/10.1007/BF02988838

Download citation

Keywords

  • multiple myeloma
  • high-dose chemo-radiotherapy
  • autologous stem cell transplantation